McMaster University

Medical Sciences
Graduate Program

Scope of Search

Ram K. Mishra

Ram K. Mishra

MSc, MS, PhD
Professor

Research Interests

Research in Dr. Mishra’s laboratory focuses on the relationship between genetic, biochemical and molecular mechanisms and neuropsychiatric disorders such as schizophrenia and Parkinson’s disease. The research team is particularly interested in the role of dopamine receptors in various disease processes, where understanding the molecular basis of their dysfunction could contribute to potential improvements in either disease detection or treatment. The laboratory has been uninterruptedly funded from CIHR, NIH, NSERC and OMHF for the last several years and currently receives major funding from these agencies.


The following projects are currently active in the lab:

  1. Role of Synapsin II in the pathophysiology of Schizophrenia: Recent efforts have led to the discovery of novel mechanisms suggesting that Synapsin II may be one of the underlying causal factors in the pathophysiology of schizophrenia.
  2. Development of allosteric drugs targeting dopamine D2L receptors: Recent work has led to the discovery of novel compounds that may be useful for the treatment of negative, positive and cognitive symptoms of schizophrenia.
  3. Role of free radicals in the development of behavioural supersensitivity: Recent work led to the caspase-independent mechanisms for cell death in haloperidol treatment.
  4. Development of novel drug delivery formulations.

Techniques:

  1. Computerized behavioural testing equipment
  2. Radioreceptor binding assays
  3. qPCR; immunoblotting
  4. Tissue culture
  5. Gene transfection

Contact

McMaster University
Health Sciences Centre

telephone: (905) 525-9140 ext. 22396
email: mishrar@mcmaster.ca

Program Area

Physiology & Pharmacology

Research Focus

Gene Expression, Mental and Neurological Disorders, cDNA Expression Array, Antipsychotic Drugs, Signal Transduction in Brain and Retina, Dopamine Receptors and Binding Proteins

Selected Publications

  • M. L. Tan, B.A. Dyck, J. Gabriele, R. P. Daya, N. Thomas, C. D. R. Sookram, D. Basu, M. Ferro, and R. K. Mishra. Synapsin II Expression in the Dorsolateral Prefrontal Cortex of Brain Specimens from Patients with Schizophrenia and Bipolar Disorder. Pharmacogenomics. 1-7, 2013. PMID 23529008.
  • M.G.R Beyaert, R.P. Daya, B.A. Dyck, R.L. Johnson and R .K. Mishra. PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia. European Neuropsychopharmacology. 23, 253-262, 2013. PMID 22658400.
  • R.P. Daya, J. Bhandari, P. Hui, Y. Tian, T. Farncombe, and R .K. Mishra. Effects of MK-801 treatment across several pre-clinical analyses including a novel assessment of brain metabolic function using PET and CT fused imaging in live rats. Neuropsychopharmacology.77, 325-333, 2014. PMID: 24140927
  • J.E. Piazza, T. Hoare, L. Molinaro, K. Terpstra, J. Bhandari, R. Selvaganapathy, B. Gupta, and R. K. Mishra. Haloperidol Intranasally administered lectin functionalized PEG-PLGA nanoparticles for the treatment of schizophrenia. European Journal of Pharmaceutics and Biopharmaceutics. 2014. PMID:24560967
  • D. Basu, Y. Tian, J. Bhandari, J. R. Jiang, P. Hui, R. L. Johnson, R. K. Mishra. Effects of the Dopamine D2 Allosteric Modulator, PAOPA, on the Expression of GRK2, Arrestin-3, ERK1/2, and on Receptor Internalization. PLOS ONE. 8(8), e70736, 2013. PMID: 23940634.